Cogent Biosciences (COGT) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Jefferies Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $20
Moomoo News15:31 ET · Ratings
Cogent Biosciences | 10-K: FY2024 Annual Report
SECFeb 25 08:41 ET · Announcements
Cogent Biosciences | 8-K: Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
SECFeb 25 08:21 ET · Announcements
Cogent Biosciences: $312 M Sufficient to Fund Ops Well Past Clinical Readouts, Into Late 2026 >COGT
Dow JonesFeb 25 08:04 ET
Cogent Biosciences: Top-line Results From SUMMIT Trial in NonAdvSM Patients Expected July >COGT
Dow JonesFeb 25 08:03 ET
Cogent Biosciences: APEX Trial Enrollment in AdvSM Patients Complete; Top-Line Results Expected in 2H
Dow JonesFeb 25 08:03 ET

Comments

Peasant Investor

Jan 29 14:03

In with the 🐳📉📉📉

$Cogent Biosciences (COGT.US)$

loading...

1

Wave_Rider

Dec 8, 2024 17:51

Quick AI research

$Cogent Biosciences (COGT.US)$
based on a quick AI research:
AdvSM is very rare. Estimated 5,000-10,000 patients in US. Limited total market size.
Based on the recent clinical data, here are Cogent Biosciences' potential advantages:
1. Efficacy Advantages:
◦ 83% ORR (mIWG criteria)
◦ 100% ORR (PPR criteria)
– Higher response rate at optimal dose (100mg BID):
– Quick response time (2.2 months)
– Potentially better than existing treatments
1. Potential Market Differentiati...

1

This_Guy

Dec 8, 2024 17:21

$Cogent Biosciences (COGT.US)$
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Positive
Strong 83% ORR in 100 mg BID dose cohort
94% of patients achieved ≥50% reduction in serum tryptase levels
Rapid median time to response of 2.2 months
82% progression-free survival rate at 24 months
100% of evaluable patients achieved ≥50% reduction in bone marrow mast cell burden
Negative
12 pat...

1

Trytosaveabit

Dec 8, 2024 16:05

Watching Monday/week! New PR / data released Sunday!

$Cogent Biosciences (COGT.US)$ Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients With Advanced Systemic Mastocytosis (AdvSM)
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID
88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID
Median time to response 2.2 months with median duration of response and median PFS not yet reach...

1

Trytosaveabit

Jun 14, 2024 06:37

Update

$Cogent Biosciences (COGT.US)$ Reuters· 3 mins ago
Cogent Biosciences Inc: Summit Trial Showed Clinically Meaningful Improvement in Skin Symptoms as Well as Objective Reduction in Skin Lesions

COGT Cogent Biosciences

Trade Overview

Capital Trend

News

Comments

Trending Stocks